Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers

doi:10.1016/j.immuni.2014.04.009

. 2014 May 15;40(5):657-68.

doi: 10.1016/j.immuni.2014.04.009. Epub 2014 Apr 24.

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers

Emilia Falkowska¹, Khoa M Le², Alejandra Ramos³, Katie J Doores⁴, Jeong Hyun Lee⁵, Claudia Blattner⁵, Alejandro Ramirez⁶, Ronald Derking⁷, Marit J van Gils⁷, Chi-Hui Liang², Ryan Mcbride⁸, Benjamin von Bredow⁹, Sachin S Shivatare¹⁰, Chung-Yi Wu¹⁰, Po-Ying Chan-Hui¹¹, Yan Liu¹², Ten Feizi¹², Michael B Zwick⁶, Wayne C Koff¹³, Michael S Seaman¹⁴, Kristine Swiderek¹¹, John P Moore¹⁵, David Evans⁹, James C Paulson¹⁶, Chi-Huey Wong¹⁰, Andrew B Ward⁵, Ian A Wilson¹⁷, Rogier W Sanders¹⁸, Pascal Poignard³, Dennis R Burton¹⁹

Affiliations

¹ Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Boston, MA 02114, USA.
² Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA.
³ Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
⁴ Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Infectious Diseases, King's College London School of Medicine, Guy's Hospital, London SE1 9RT, UK.
⁵ International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
⁶ Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.
⁷ Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
⁸ Departments of Cell and Molecular Biology and Chemical Physiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
⁹ Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin 53711, USA.
¹⁰ Genomics Research Center, Academia Sinica, Nankang, Taipei 115, Taiwan.
¹¹ Theraclone Sciences, Inc., Seattle, Washington 98104, USA.
¹² Glycosciences Laboratory, Department of Medicine, Imperial College London, London W12 ONN, UK.
¹³ International AIDS Vaccine Initiative, New York, NY 10038, USA.
¹⁴ Beth Israel Deaconess Medical Center, Center for Virology and Vaccine Research, Boston, MA, 02215, USA.
¹⁵ Weill Medical College of Cornell University, New York, NY 10004, USA.
¹⁶ Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
¹⁷ International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA; Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
¹⁸ Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; Weill Medical College of Cornell University, New York, NY 10004, USA.
¹⁹ Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Boston, MA 02114, USA. Electronic address: burton@scripps.edu.

PMID: 24768347
PMCID: PMC4070425
DOI: 10.1016/j.immuni.2014.04.009

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers

Emilia Falkowska et al. Immunity. 2014.

. 2014 May 15;40(5):657-68.

doi: 10.1016/j.immuni.2014.04.009. Epub 2014 Apr 24.

Authors

Affiliations

¹ Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Boston, MA 02114, USA.
² Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA.
³ Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
⁴ Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Infectious Diseases, King's College London School of Medicine, Guy's Hospital, London SE1 9RT, UK.
⁵ International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
⁶ Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.
⁷ Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
⁸ Departments of Cell and Molecular Biology and Chemical Physiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
⁹ Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin 53711, USA.
¹⁰ Genomics Research Center, Academia Sinica, Nankang, Taipei 115, Taiwan.
¹¹ Theraclone Sciences, Inc., Seattle, Washington 98104, USA.
¹² Glycosciences Laboratory, Department of Medicine, Imperial College London, London W12 ONN, UK.
¹³ International AIDS Vaccine Initiative, New York, NY 10038, USA.
¹⁴ Beth Israel Deaconess Medical Center, Center for Virology and Vaccine Research, Boston, MA, 02215, USA.
¹⁵ Weill Medical College of Cornell University, New York, NY 10004, USA.
¹⁶ Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
¹⁷ International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA; Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
¹⁸ Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; Weill Medical College of Cornell University, New York, NY 10004, USA.
¹⁹ Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Boston, MA 02114, USA. Electronic address: burton@scripps.edu.

PMID: 24768347
PMCID: PMC4070425
DOI: 10.1016/j.immuni.2014.04.009

Abstract

Broadly neutralizing HIV antibodies are much sought after (a) to guide vaccine design, both as templates and as indicators of the authenticity of vaccine candidates, (b) to assist in structural studies, and (c) to serve as potential therapeutics. However, the number of targets on the viral envelope spike for such antibodies has been limited. Here, we describe a set of human monoclonal antibodies that define what is, to the best of our knowledge, a previously undefined target on HIV Env. The antibodies recognize a glycan-dependent epitope on the prefusion conformation of gp41 and unambiguously distinguish cleaved from uncleaved Env trimers, an important property given increasing evidence that cleavage is required for vaccine candidates that seek to mimic the functional HIV envelope spike. The availability of this set of antibodies expands the number of vaccine targets on HIV and provides reagents to characterize the native envelope spike.

PubMed Disclaimer

Figures

**Figure 1. PGT151–158 neutralization of an indicator panel of 5 pseudoviruses**
Serial dilutions of antibody were preincubated with pseudovirus for 1 hour and then added to TZM-bl cells. Three days post-infection luciferase values were measured and % neutralization was calculated. Data is one representative experiment of at least two replicate experiments and is presented as mean of two replicate wells +/− SEM.

**Figure 2. PGT151 and PGT152 binding to different forms of Env**
(A) PGT151 and PGT152 do not bind to JR-FL gp120 monomer as measured by ELISA. (B) PGT151 binds to native, cleaved (cl) but not to uncleaved (uncl) JR-FL E168K trimers expressed on the surface of 293T cells as measured by flow cytometry, and (C) PGT151 and PGT152 bind to cleaved soluble BG505 SOSIP.664 gp140 trimers but not to the corresponding uncleaved gp140 trimers as measured by ELISA. See also Figure S2. Data for (A) and (C) is presented as mean of two replicates +/− SEM. Data for (B) is a representative experiment of two replicate experiments.

**Figure 3. PGT151-PGT158 bind complex carbohydrates**
(A) PGT151 and PGT152 neutralization of JR-CSF pseudovirus generated (i) in the presence of the glycosidase inhibitor swainsonine, which prevents the formation of complex glycans by inhibiting the trimming of mannose residues from the Man-α6 arm of the GlcNAcMan₅GlcNAc₂ structure or (ii) in 293S cells (GNT1^−/− cells), a cell line that is deficient in N-acetylglucosaminyltransferase I and is unable to add a GlcNAc residue to the Man₅GlcNAc₂ structure to permit processing to complex glycans. Neutralization of JR-SCF pseudovirus by 2G12 is not affected by either (i) or (ii) since it binds exclusively to high-mannose glycans on the glycan shield of Env. Data is presented as mean +/− SEM. (B) Glycan microarray analysis reveals PGT151-PGT158 preferentially bind tetraantennary complex carbohydrates and PGT151 additionally binds a triantennary glycan as detected on the Wong glycan array. Data is presented as mean +/− SD. (C) Glycan microarray analysis using the CFG microarray additionally reveals that all PGT151 family MAbs except PGT153 preferentially bind triantennary complex carbohydrates; and (D) PGT151 and PGT152 bind a tetrantennary complex carbohydrate on the neoglycolipid microarray. The symbols for common monosaccharides are as follows: purple diamonds represent sialic acid, yellow circles represent galactose, red triangles represent fucose, blue squares represent N-acetyl glucosamine and green circles represent mannose. See also Tables S4–S5. Data for the CFG microarray is presented as mean +/− SEM.

**Figure 4. PGT151 neutralization of viruses containing N611A, N637A, E647A single and double alanine substitutions**
Serial dilutions of antibody (A) PGT151 and (B) PGV04, used as a control, were preincubated with pseudovirus for 1 hour and then added to TZM-bl cells. Three days post-infection luciferase values were measured and % neutralization was calculated. See also Figure S4. Data are from a representative experiment of at least two replicate experiments and are presented as mean values of two replicate wells +/− SEM.

**Figure 5. ADCC by PGT151 and PGT152**
(A) PGT151 and (B) PGT152 were titered for ADCC activity against target cells infected with HIV-1 NL4–3, YU2, JR-CSF and SIVmac239, and using an NK cell line (KHYG-1) expressing CD16 as the effector cell. The killing of virus-infected cells by ADCC is indicated by a loss of relative light units (RLU). SIVmac239 is used as a negative control and HIVIG is used as a positive control. Data are presented as mean values of three replicates +/− SEM.

See this image and copyright information in PMC

Cited by

Conjugation of Native-Like HIV-1 Envelope Trimers onto Liposomes Using EDC/Sulfo-NHS Chemistry: Requirements and Limitations.
Suleiman E, Mayer J, Lehner E, Kohlhauser B, Katholnig A, Batzoni M, Damm D, Temchura V, Wagner A, Überla K, Vorauer-Uhl K. Suleiman E, et al. Pharmaceutics. 2020 Oct 16;12(10):979. doi: 10.3390/pharmaceutics12100979. Pharmaceutics. 2020. PMID: 33081278 Free PMC article.
Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies.
Grimm SK, Battles MB, Ackerman ME. Grimm SK, et al. PLoS One. 2015 Feb 17;10(2):e0117227. doi: 10.1371/journal.pone.0117227. eCollection 2015. PLoS One. 2015. PMID: 25688555 Free PMC article.
Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
Wieczorek L, Krebs SJ, Kalyanaraman V, Whitney S, Tovanabutra S, Moscoso CG, Sanders-Buell E, Williams C, Slike B, Molnar S, Dussupt V, Alam SM, Chenine AL, Tong T, Hill EL, Liao HX, Hoelscher M, Maboko L, Zolla-Pazner S, Haynes BF, Pensiero M, McCutchan F, Malek-Salehi S, Cheng RH, Robb ML, VanCott T, Michael NL, Marovich MA, Alving CR, Matyas GR, Rao M, Polonis VR. Wieczorek L, et al. J Virol. 2015 Aug;89(15):7478-93. doi: 10.1128/JVI.00412-15. Epub 2015 May 13. J Virol. 2015. PMID: 25972551 Free PMC article.
Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.
Barbian HJ, Decker JM, Bibollet-Ruche F, Galimidi RP, West AP Jr, Learn GH, Parrish NF, Iyer SS, Li Y, Pace CS, Song R, Huang Y, Denny TN, Mouquet H, Martin L, Acharya P, Zhang B, Kwong PD, Mascola JR, Verrips CT, Strokappe NM, Rutten L, McCoy LE, Weiss RA, Brown CS, Jackson R, Silvestri G, Connors M, Burton DR, Shaw GM, Nussenzweig MC, Bjorkman PJ, Ho DD, Farzan M, Hahn BH. Barbian HJ, et al. mBio. 2015 Apr 21;6(2):e00296-15. doi: 10.1128/mBio.00296-15. mBio. 2015. PMID: 25900654 Free PMC article.
Identification of a novel broadly HIV-1-neutralizing antibody from a CRF01_AE-infected Chinese donor.
Ju B, Li D, Ren L, Hou J, Hao Y, Liang H, Wang S, Zhu J, Wei M, Shao Y. Ju B, et al. Emerg Microbes Infect. 2018 Nov 1;7(1):174. doi: 10.1038/s41426-018-0175-1. Emerg Microbes Infect. 2018. PMID: 30382080 Free PMC article.

See all "Cited by" articles

References

1. Alpert MD, Heyer LN, Williams DEJ, Harvey JD, Greenough T, Allhorn M, Evans DT. Articles of Significant Interest Selected from This Issue by the Editors. J. Virol. 2012;86:11955–11955.
1. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang H-W, Shekhar K, Gupta S, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013;503:224–228. - PMC - PubMed
1. Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, Torrents de la Peña A, Cupo A, Julien JP, van Gils M, et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity. 2014 - PMC - PubMed
1. Blixt O, Head S, Mondala T, Scanlan C, Huflejt ME, Alvarez R, Bryan MC, Fazio F, Calarese D, Stevens J, et al. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc. Natl. Acad. Sci. U.S.a. 2004;101:17033–17038. - PMC - PubMed
1. Bonomelli C, Doores KJ, Dunlop DC, Thaney V, Dwek RA, Burton DR, Crispin M, Scanlan CN. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS ONE. 2011;6:e23521. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations

[1] Alpert MD, Heyer LN, Williams DEJ, Harvey JD, Greenough T, Allhorn M, Evans DT. Articles of Significant Interest Selected from This Issue by the Editors. J. Virol. 2012;86:11955–11955.

[2] Alpert MD, Heyer LN, Williams DEJ, Harvey JD, Greenough T, Allhorn M, Evans DT. Articles of Significant Interest Selected from This Issue by the Editors. J. Virol. 2012;86:11955–11955.

[3] Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang H-W, Shekhar K, Gupta S, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013;503:224–228. - PMC - PubMed

[4] Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang H-W, Shekhar K, Gupta S, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013;503:224–228. - PMC - PubMed

[5] Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, Torrents de la Peña A, Cupo A, Julien JP, van Gils M, et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity. 2014 - PMC - PubMed

[6] Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, Torrents de la Peña A, Cupo A, Julien JP, van Gils M, et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity. 2014 - PMC - PubMed

[7] Blixt O, Head S, Mondala T, Scanlan C, Huflejt ME, Alvarez R, Bryan MC, Fazio F, Calarese D, Stevens J, et al. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc. Natl. Acad. Sci. U.S.a. 2004;101:17033–17038. - PMC - PubMed

[8] Blixt O, Head S, Mondala T, Scanlan C, Huflejt ME, Alvarez R, Bryan MC, Fazio F, Calarese D, Stevens J, et al. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc. Natl. Acad. Sci. U.S.a. 2004;101:17033–17038. - PMC - PubMed

[9] Bonomelli C, Doores KJ, Dunlop DC, Thaney V, Dwek RA, Burton DR, Crispin M, Scanlan CN. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS ONE. 2011;6:e23521. - PMC - PubMed

[10] Bonomelli C, Doores KJ, Dunlop DC, Thaney V, Dwek RA, Burton DR, Crispin M, Scanlan CN. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS ONE. 2011;6:e23521. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers

Affiliations

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers

Authors

Affiliations

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Associated data

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Associated data

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources